Matching articles for "medroxyprogesterone"
Drugs for Menopausal Symptoms
The Medical Letter on Drugs and Therapeutics • March 4, 2024; (Issue 1697)
The primary symptoms of menopause are genitourinary
and vasomotor. The genitourinary syndrome
of menopause (GSM) includes symptoms such as
burning, irritation, dryness, dyspareunia, dysuria,
and recurrent...
The primary symptoms of menopause are genitourinary
and vasomotor. The genitourinary syndrome
of menopause (GSM) includes symptoms such as
burning, irritation, dryness, dyspareunia, dysuria,
and recurrent urinary tract infection. Vasomotor
symptoms (VMS; hot flashes, night sweats) often
disrupt sleep.
Choice of Contraceptives
The Medical Letter on Drugs and Therapeutics • May 15, 2023; (Issue 1676)
Intrauterine devices (IUDs) and the etonogestrel
implant are the most effective reversible contraceptive
methods available. Hormonal oral contraceptives,
patches, rings, and injectables are also effective...
Intrauterine devices (IUDs) and the etonogestrel
implant are the most effective reversible contraceptive
methods available. Hormonal oral contraceptives,
patches, rings, and injectables are also effective in
preventing pregnancy. When used alone, barrier and
behavioral methods generally have higher failure
rates than other methods (see Table 1). Selection of
a contraceptive method is usually based on patient-specific factors and personal preference
Phexxi - A Nonhormonal Contraceptive Gel
The Medical Letter on Drugs and Therapeutics • August 24, 2020; (Issue 1605)
The FDA has approved Phexxi (Evofem), a
nonhormonal prescription-only vaginal gel containing
lactic acid, citric acid, and potassium bitartrate, for
prevention of pregnancy. The gel is intended for...
The FDA has approved Phexxi (Evofem), a
nonhormonal prescription-only vaginal gel containing
lactic acid, citric acid, and potassium bitartrate, for
prevention of pregnancy. The gel is intended for on-demand
contraception; it is not effective when used
after intercourse. It was previously approved for
use as a vaginal lubricant (Amphora), but was never
marketed.
Addendum: Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms
The Medical Letter on Drugs and Therapeutics • July 29, 2019; (Issue 1577)
In our article on Bijuva, the oral fixed-dose combination of estradiol and progesterone (Med Lett Drugs Ther 2019; 61:99), Table 1 should have included single-ingredient oral formulations of estradiol and...
In our article on Bijuva, the oral fixed-dose combination of estradiol and progesterone (Med Lett Drugs Ther 2019; 61:99), Table 1 should have included single-ingredient oral formulations of estradiol and progesterone (see below). They will be added to the table as it appears online, along with medroxyprogesterone (Provera, and generics), another single-ingredient progestin available for use in women with an intact uterus who take systemic estrogen for menopausal symptoms. Taking generic estradiol and progesterone separately may be less convenient than taking Bijuva, but they cost less and allow for more dosing flexibility.
Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms
The Medical Letter on Drugs and Therapeutics • July 1, 2019; (Issue 1575)
The FDA has approved Bijuva (TherapeuticsMD), a
fixed-dose combination of estradiol and progesterone,
for oral treatment of moderate to severe vasomotor
symptoms (hot flashes) due to menopause in women
with...
The FDA has approved Bijuva (TherapeuticsMD), a
fixed-dose combination of estradiol and progesterone,
for oral treatment of moderate to severe vasomotor
symptoms (hot flashes) due to menopause in women
with an intact uterus. The manufacturer is marketing
Bijuva as "the first and only FDA-approved combination
of bio-identical estradiol and bio-identical progesterone
in a single daily oral capsule".
Choice of Contraceptives
The Medical Letter on Drugs and Therapeutics • October 8, 2018; (Issue 1557)
Intrauterine devices (IUDs) and the etonogestrel
implant are the most effective reversible contraceptive
methods available. Hormonal oral contraceptives,
patches, rings, and injectables are also highly...
Intrauterine devices (IUDs) and the etonogestrel
implant are the most effective reversible contraceptive
methods available. Hormonal oral contraceptives,
patches, rings, and injectables are also highly effective
in preventing pregnancy. When used alone, barrier and
fertility-based methods generally have higher failure
rates than other methods.
Drugs for Menopausal Symptoms
The Medical Letter on Drugs and Therapeutics • November 7, 2016; (Issue 1507)
The primary symptoms of menopause are
genitourinary and vasomotor. A thin, dry vaginal lining
and thin urethral mucosa can cause vaginal and vulvar
burning and irritation, pain during intercourse, and...
The primary symptoms of menopause are
genitourinary and vasomotor. A thin, dry vaginal lining
and thin urethral mucosa can cause vaginal and vulvar
burning and irritation, pain during intercourse, and an
increased risk of urinary tract infections. Vasomotor
symptoms ("hot flashes") cause daytime discomfort
and night sweats that may disrupt sleep.
Conjugated Estrogens/Bazedoxifene (Duavee) for Menopausal Symptoms and Prevention of Osteoporosis
The Medical Letter on Drugs and Therapeutics • April 28, 2014; (Issue 1441)
The FDA has approved Duavee (Pfizer), a fixed-dose
combination of conjugated estrogens and the
new selective estrogen receptor modulator (SERM)
bazedoxifene, for treatment of moderate to severe
vasomotor...
The FDA has approved Duavee (Pfizer), a fixed-dose
combination of conjugated estrogens and the
new selective estrogen receptor modulator (SERM)
bazedoxifene, for treatment of moderate to severe
vasomotor symptoms and for prevention of osteoporosis
in postmenopausal women with an intact uterus.
Bazedoxifene is an estrogen agonist/antagonist with
estrogen-like effects on bone and antiestrogen effects
on the uterus. It is the second SERM to be approved
for prevention of osteoporosis; raloxifene (Evista, and
generics) has been available as a single agent for this
indication since 1997.
Drugs for Postmenopausal Osteoporosis
The Medical Letter on Drugs and Therapeutics • November 1, 2011; (Issue 111)
Osteoporosis is characterized by low bone mass with
microarchitectural disruption and skeletal fragility that
results in an increased risk of fracture. The diagnosis
has traditionally been established by...
Osteoporosis is characterized by low bone mass with
microarchitectural disruption and skeletal fragility that
results in an increased risk of fracture. The diagnosis
has traditionally been established by bone densitometry,
which is generally reported in terms of standard
deviations (SD) from mean values in young adults (T-score). The World Health Organization (WHO) has
defined normal bone mineral density (BMD) for
women as a value within one SD of the young adult
mean. Values 2.5 SD or more below the mean (T score
-2.5) are defined as osteoporosis. The WHO has developed
a computerized model (FRAX) that predicts the
10-year probability of a hip fracture or any other
major osteoporotic fracture based on clinical risk factors
and BMD at the femoral neck.
Choice of Contraceptives
The Medical Letter on Drugs and Therapeutics • December 1, 2010; (Issue 100)
The choice of which contraceptive to use may vary from one stage of reproductive life to another. Intrauterine devices (IUDs), progestin implants and sterilization are the most effective contraceptive methods...
The choice of which contraceptive to use may vary from one stage of reproductive life to another. Intrauterine devices (IUDs), progestin implants and sterilization are the most effective contraceptive methods available to women. Hormonal contraceptives, when used correctly, are also highly effective in preventing pregnancy. Barrier and fertility-based methods
have the highest rate of failure.
Drugs for Postmenopausal Osteoporosis
The Medical Letter on Drugs and Therapeutics • October 1, 2008; (Issue 74)
Osteoporosis is characterized by low bone mass with microarchitectural disruption and skeletal fragility that results in an increased risk of fracture. The diagnosis has traditionally been established by bone...
Osteoporosis is characterized by low bone mass with microarchitectural disruption and skeletal fragility that results in an increased risk of fracture. The diagnosis has traditionally been established by bone densitometry, which is generally reported in terms of standard deviations (SD) from mean values in young adults (T score). The World Health Organization (WHO) has defined normal bone mineral density (BMD) for women as a value within one SD of the young adult mean. Values 2.5 SD (T score -2.5) or more below the mean are defined as osteoporosis. The WHO has developed a computerized model (FRAX) that predicts the 10-year probability of hip fracture based on clinical risk factors and BMD at the femoral neck.
Angeliq for Treatment of Menopausal Symptoms
The Medical Letter on Drugs and Therapeutics • February 12, 2007; (Issue 1254)
A combination tablet containing estradiol and drospirenone (Angeliq - Berlex) recently became available for treatment of moderate to severe menopausal symptoms in women with an intact uterus. Since the last...
A combination tablet containing estradiol and drospirenone (Angeliq - Berlex) recently became available for treatment of moderate to severe menopausal symptoms in women with an intact uterus. Since the last Medical Letter issue reviewing such devices,1 more continuous glucose monitoring (CGM) systems have become available. Five devices available now, and two expected to be marketed soon, are listed in the table on page 14. The FDA has approved continuous glucose devices only for the observation of glucose trends.
Drugs for Prevention and Treatment of Postmenopausal Osteoporosis
The Medical Letter on Drugs and Therapeutics • October 1, 2005; (Issue 38)
Many drugs are now marketed for treatment of postmenopausal osteoporosis, but questions remain about their...
Many drugs are now marketed for treatment of postmenopausal osteoporosis, but questions remain about their use.
Drugs for Prevention and Treatment of Postmenopausal Osteoporosis
The Medical Letter on Drugs and Therapeutics • November 1, 2002; (Issue 3)
Many drugs are now marketed for treatment of post-menopausal osteoporosis (PD Delmas, Lancet 2002; 359:2018). Prevention of this disorder has been complicated by the news that hormone replacement therapy (HRT),...
Many drugs are now marketed for treatment of post-menopausal osteoporosis (PD Delmas, Lancet 2002; 359:2018). Prevention of this disorder has been complicated by the news that hormone replacement therapy (HRT), which many women have been taking to prevent osteoporosis, increases the incidence of coronary heart disease and that of breast cancer, stroke and pulmonary embolism as well (Medical Letter 2002; 44:78).
Generic drugs
The Medical Letter on Drugs and Therapeutics • October 14, 2002; (Issue 1141)
When patents expire on brand-name drugs and generic formulations become available, patients and managed care organizations may express a preference for the lower-cost generics. Are they equivalent to the...
When patents expire on brand-name drugs and generic formulations become available, patients and managed care organizations may express a preference for the lower-cost generics. Are they equivalent to the brand-name product?
Drugs For Prevention and Treament of Postmenopausal Osteoporosis
The Medical Letter on Drugs and Therapeutics • October 16, 2000; (Issue 1090)
Many drugs are now marketed for prevention and treatment of postmenopausal osteoporosis. All regimens should include an adequate intake of calcium and vitamin...
Many drugs are now marketed for prevention and treatment of postmenopausal osteoporosis. All regimens should include an adequate intake of calcium and vitamin D.
Drugs of Choice for Cancer Chemotherapy
The Medical Letter on Drugs and Therapeutics • March 14, 1997; (Issue 996)
The tables that follow list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants....
The tables that follow list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. For most of the cancers listed, surgery and/or radiation therapy are part of the management of the disease. Anticancer drugs and their adverse effects are listed in Table II.
Choice of Contraceptives
The Medical Letter on Drugs and Therapeutics • February 3, 1995; (Issue 941)
New information about contraceptives continues to become available. The commonly used methods of reversible contraception are listed...
New information about contraceptives continues to become available. The commonly used methods of reversible contraception are listed below.
Choice of Contraceptives
The Medical Letter on Drugs and Therapeutics • December 11, 1992; (Issue 885)
The commonly used methods of reversible contraception are listed in the table below. Additional information is available in RA Hatcher et al, Contraceptive Technology, 1990-1992, 15th ed, New York:Irvington,...
The commonly used methods of reversible contraception are listed in the table below. Additional information is available in RA Hatcher et al, Contraceptive Technology, 1990-1992, 15th ed, New York:Irvington, 1990.